Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice -HOPE

Trial Profile

Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice -HOPE

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Intermediate uveitis; Panuveitis; Posterior uveitis
  • Focus Therapeutic Use
  • Acronyms HOPE
  • Sponsors AbbVie
  • Most Recent Events

    • 22 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 19 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top